Literature DB >> 11807633

Simple prognostic model for patients with multiple myeloma: a single-center study in Japan.

M Kaneko1, Y Kanda, K Oshima, Y Nannya, M Suguro, R Yamamoto, A Chizuka, T Hamaki, T Matsuyama, N Takezako, A Miwa, A Togawa.   

Abstract

The range of survival duration in myeloma patients is wide and several percent of patients live longer than 10 years. Therefore, a precise prediction of survival for the individual patient is required to decide treatment. We evaluated possible prognostic factors at diagnosis for 116 Japanese patients with multiple myeloma. Twelve parameters reported to affect survival were analyzed using a log rank test and stepwise Cox proportional hazards regression. Factors identified as adversely affecting survival were age over 60 years, male sex, blood hemoglobin less than 8.5 g/dl, platelets less than 100 x 10(9)/l, serum creatinine level more than 2.0 mg/dl, serum C-reactive protein (CRP) level more than 6.0 mg/l, and serum beta2-microglobulin level more than 6.0 mg/l. Among them, only high age and high serum CRP level were independently prognostic for poor survival. In conclusion, we have established a simple prognostic model for Japanese myeloma patients only, using factors that can be determined in routine examinations without the need of subjective information.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11807633     DOI: 10.1007/s00277-001-0388-5

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  2 in total

1.  Preoperative elevation of serum C--reactive protein is predictive for prognosis in myeloma bone disease after surgery.

Authors:  A Zahlten-Hinguranage; H Goldschmidt; F W Cremer; G Egerer; T Moehler; D Witte; L Bernd; D Sabo; F Zeifang
Journal:  Br J Cancer       Date:  2006-09-12       Impact factor: 7.640

2.  The effect of marrow stromal cells on TRAF6 expression levels in myeloma cells.

Authors:  Hongming Huang; Zhongwei Sun; Xudong Wang; Xinxin Liu; Wenxiu Na; Ruirong Xu; Runsheng Ding; Hong Liu
Journal:  Oncol Lett       Date:  2017-06-06       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.